Sidley represented Precision NeuroMed Inc. (PNM), a clinical-stage biotechnology company advancing precision therapeutics for central nervous system (CNS) diseases, in its strategic partnership with Brainlab SE (Brainlab), a global leader in digital medical technology. Under a Joint Development and Commercialization Agreement, the companies will collaborate to develop and commercialize a cloud-based, AI-enabled treatment planning platform for convection enhanced delivery (CED) to the brain. The partnership combines Brainlab’s expertise in medical imaging digitalization and surgical workflow integration with PNM’s proprietary molecular flow simulation software to create a CED Treatment Planning System designed to optimize and personalize drug distribution directly into brain tissue. As part of the agreement, Brainlab has also received an equity interest in PNM.

The Sidley team was led by Joshua T. Hofheimer (Technology and Life Sciences Transactions), and included Collin J. Marshall (Technology and Life Sciences Transactions); Francesca Blythe, Sheri Porath Rockwell, and Eleanor Dodding (Privacy and Cybersecurity); and Torrey Cope (Food, Drug and Medical Device).